Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing antibody-based therapies for fibro-inflammatory diseases. Its lead program, nebokitug, is designed to neutralize the soluble protein CCL24 and is being studied for primary sclerosing cholangitis and other immune-fibrotic conditions. The company is headquartered in Tel Aviv, Israel and is publicly listed on Nasdaq in the United States.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueNebokitug and related clinical development activities targeting CCL24-driven fibrosis and inflammation.
Preclinical and translational work to expand nebokitug into additional fibro-inflammatory indications.
Out-licensing, collaboration, and strategic partnership opportunities around the nebokitug asset.
Customers
Chemomab does not sell commercial medicines to end patients; its economic counterparties are primarily pharmaceutical and biotechnology partners, regulators, investigators, and clinical trial sites. The company’s development programs are aimed at patients with severe fibro-inflammatory diseases, especially primary sclerosing cholangitis, where treatment options are limited and unmet need is high.
Potential licensees or collaborators that may fund development or commercialize nebokitug in defined territories or indications.
FDA and other health authorities that review trial design, endpoints, and approval pathways for nebokitug.
Investigators, hospitals, and trial networks that enroll PSC and other fibro-inflammatory patients into studies.
Patients with PSC and related conditions who are the intended beneficiaries of the company’s therapies.
Strategy
Chemomab’s strategy centers on advancing nebokitug through late-stage clinical development in PSC and using translational data to support broader fibro-inflammatory indications. The company is also pursuing strategic partnering options, which can provide external validation and a path to broader development and commercialization.
PSC is the lead indication and the clearest path to value creation for nebokitug.
Biomarker and mechanistic data help support disease-modifying claims and partnering interest.
A partner can provide capital, development scale, and commercialization reach.
Additional fibro-inflammatory diseases could expand the asset’s commercial opportunity.
Geography
Chemomab is headquartered in Tel Aviv, Israel, while its equity is listed on Nasdaq in the United States. Its development work is global in nature because clinical trials, regulatory interactions, and partnering discussions can span the U.S., Israel, Europe, and other research markets.
Risks
Chemomab’s business depends heavily on the clinical and regulatory success of a single lead asset, so trial outcomes and approval timing are major value drivers. As a development-stage biotech, it also faces financing, partnering, and execution risk, while broader industry risks include competition, safety concerns, and uncertainty around biomarker-to-clinical translation.
Nebokitug is the lead asset, so negative efficacy or safety results would materially impair the company.
Exposure: PSC Phase 3 and follow-on indications
Approval depends on FDA acceptance of endpoints, trial design, and evidence package.
Exposure: PSC development pathway
Clinical-stage biotech companies typically require external capital before commercialization.
Exposure: Operating runway and trial funding
The company is pursuing strategic options that may not close on favorable terms or timing.
Exposure: Out-licensing and collaboration discussions
Other therapies or changing scientific views could reduce the perceived value of CCL24 targeting.
Exposure: Fibro-inflammatory disease market
Accounting
Judgemental itemsClinical trial costs, CRO accruals, and development spend drive the income statement.
Impact: Affects operating loss and period-to-period comparability
Equity awards are common in biotech and can be a significant non-cash expense.
Impact: Affects reported operating expenses and dilution analysis
Trial vendor invoices and patient enrollment timing require management estimates.
Impact: Can shift expenses between quarters
Partnering arrangements may require judgment on performance obligations and timing.
Impact: Could affect revenue recognition if deals are signed
Similar listed companies
Publicly listed companies with a comparable business focus.
AgomAb Therapeutics NV
AGMB · Biological Products, (No Diagnostic Substances)
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company based in Antwerp, Belgium, focused on developing therapies for fibro-inflammatory diseases.
Apogee Therapeutics, Inc.
Biological Products, (No Diagnostic Substances)
Mirum Pharmaceuticals, Inc.
MIRM · Pharmaceutical Preparations
Mirum Pharmaceuticals is a U.S.-based biopharmaceutical company focused on rare diseases, with a commercial portfolio centered on bile acid and cholestatic liver disorder therapies.
Climb Bio, Inc.
CLYM · Pharmaceutical Preparations
C4 Therapeutics, Inc.
CCCC · Biological Products, (No Diagnostic Substances)
Delcath Systems, Inc
DCTH · Surgical & Medical Instruments & Apparatus
Delcath Systems is a U.S.-based interventional oncology company focused on treating cancers that are primary to, or have spread to, the liver.
Last updated: 18/07/2026